Navigation Links
Dr. Wayne Hachey Joins Protein Sciences' Leadership Team

MERIDEN, Conn., Feb. 20, 2013 /PRNewswire/ -- Protein Sciences Corporation announced today that Wayne Hachey , DO (Colonel, U.S. Army, ret.) has joined the Company's management as Head, Government and Clinical Affairs.  Dr. Hachey is a physician who has dedicated 28 years of service to the military healthcare system, including six years as a subject matter expert advising senior Department of Defense (DoD) leadership regarding the DoD's vaccine policy.  He was also responsible for developing the overarching DoD mitigation response to pandemic influenza and directed the implementation of that policy during the 2009 H1N1 pandemic.  Most recently, Dr. Hachey served as the Chief of Public Health for the 1st Medical Brigade in Afghanistan where he provided public health leadership to protect over 98,000 U.S. troops.  He is board certified in Public Health, Pediatrics and Neonatal-Perinatal Medicine and has won numerous awards, including the Defense Meritorious Service Medal, Meritorious Service Medal, NATO (Afghanistan) and Afghanistan Campaign Medal and Unit Combat Patch. 

Dr. Manon Cox , MBA, President and CEO of Protein Sciences commented, "We are delighted to welcome Dr. Hachey to our team."  She added, "In his new role, his primary responsibility will be to play a key role in our Company's interactions with government agencies."

Dr. Hachey will represent Protein Sciences at the following meetings this week where the Company's revolutionary new influenza vaccine Flublok® will be presented:

The Advisory Committee on Immunization Practices (ACIP) Meeting
February 20-21, 2013
CDC, Atlanta, GA

2013 AAAAI Annual Meeting
February 22-26, 2013
San Antonio, TX

About Us

Protein Sciences Corporation is a vaccine development and protein production company based in Meriden, CT that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceu­ticals. Our proprietary baculovirus expression vector system (BEVS) technology provides a fast, reliable and inexpensive platform for the production of high quality recombinant proteins, making it a powerful tool for producing vaccines and therapeutics when they are needed most.  BEVS technology is covered by broad patents that include our proprietary expresSF+® cell line that we use to make all of our products.

On January 16, the FDA approved Flublok, a novel influenza vaccine for the prevention of influenza in adults aged 18-49 years old. The FDA has called Flublok a revolutionary vaccine as no eggs or live influenza virus is used in its manufacturing process. In addition, the product does not contain a preservative (e.g., thimerosal), latex, adjuvants or other additives. 

Learn more at and

SOURCE Protein Sciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
2. Michael Cusumano, MITs Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors
3. Robert Farrell Joins Bionovos Board of Directors
4. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
5. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
6. First Choice Rehabilitation Specialists Joins Select Medical
7. Excel Life Sciences Joins DATATRAKs Connect Partner Program
8. Marina Biotech, Inc. Joins OTCQX
9. Richard H. Scheuermann, Ph.D. Joins J. Craig Venter Institute as Director of Informatics
10. Dr. David L. Blecker MD, MPH, F.A.C.P. Joins Inergetics Advisory Board to Co-Develop and Market Products to Penetrate Nephrology Market
11. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/12/2016)... -- , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
Breaking Biology News(10 mins):